日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
China
Home / China / Health

Prospective vaccine in Phase II trial

By Yang Wanli | China Daily | Updated: 2020-04-11 08:14
Share
Share - WeChat
Wang Li, a 45-year-old volunteer, receives the recombinant novel coronavirus (COVID-19) vaccine inoculation in Wuhan, Central China's Hubei province, on March 24, 2020. [Photo by Zhu Xingxin/chinadaily.com.cn]

500 symptom-free volunteers to take part in test conducted in Hubei's capital

A recombinant novel coronavirus vaccine, which is China's first vaccine candidate to enter clinical human testing, began recruiting participants for its Phase II clinical trial on Thursday. There is a need for 500 volunteers, five times the number used in the Phase I trial conducted in March.

Participants will be divided into three groups-a moderate dose, a low dose and a control group-according to Cansino Biologics Inc, a Tianjin-based company responsible for the vaccine's development.

It said 250 participants will be involved in the moderate dose test while the rest will be equally distributed into the low dose and control group.

The vaccine candidate is made through recombinant DNA techniques, which typically involve taking a gene from one organism and inserting it into the DNA of another.

The recruitment notification says participants should be aged 18 or above, with neither a previous history of allergies to vaccinations nor a history of COVID-19 infection.

The trial will be conducted in Wuhan, the hardest-hit region in China, so participants are also required to have a "green code"-an indication of being symptom free according to a health code app, which includes basic health information and travel history-which was developed due to the pandemic.

The vaccine candidate, known as Ad5-nCoV, was jointly developed by Cansino and the Institute of Biotechnology of the Academy of Military Medical Sciences.

The Phase I trial, which included 108 test subjects, took place at Tongji Hospital in Wuhan, Hubei province, last month. According to the Chinese Clinical Trial Registry, the single-center, open and dose-escalation Phase I trial tested the safety of and tolerance for the vaccine candidate in healthy adults.

Adverse reactions seen in the Phase I trial included fever and pain at the inoculation site and the joints. The group that received a high dose reported more fevers, but the symptom usually disappeared within 24 hours.

Unlike the Phase I trial that required participants to undergo 14-day quarantine restrictions in a designated place after being vaccinated, the Phase II clinical trial allows participants to conduct self-quarantine at home.

In the six months after vaccination, investigators will continue to monitor all participants and visit each one four times.

The COVID-19 vaccine trial in China follows the first trial launched in the United States at Kaiser Permanente Washington Health Research Institute in Seattle, Washington, which evaluated the US drug company Moderna's mRNA-1273 vaccine in mid-March. Moderna's trial used a gene-based method that uses messenger RNA to trigger an immune response in the target individual. Another candidate, the INO-4800 DNA vaccine by Inovio Pharmaceuticals in the US, also entered Phase I clinical human testing this month.

The Ad5-nCoV in China is developed with Cansino's adenoviral vector-based vaccine, a platform which was key to enabling the company to develop its Ebola virus vaccine, Ad5-EBOV, in only three years.

Zheng Zhongwei, an official at the National Health Commission, said at a recent news conference that there are currently eight institutions in China working on developing vaccines along five technical routes.

He said all vaccine research is carried out according to appropriate laws, standards and norms. "Our goal is to make sure the vaccine against the novel coronavirus will be put into use as soon as possible, based on the premise of ensuring its safety and effectiveness," Zheng said.

Zou Shuo contributed to this story.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 国产精品日韩在线观看 | 国产成人在线播放视频 | 欧美成人午夜免费完成 | 欧洲精品一区二区三区在线观看 | 精品国产一区二区三区成人影院 | 四虎影视免费观看免费观看 | 国产成人99久久亚洲综合精品 | 高清不卡一区二区 | 五月综合激情婷婷六月 | 免费二区 | 狠狠草视频 | 免费在线成人 | 国产精品久久久久久久久免费 | 欧美视频99 | 午夜人成| 久久99国产伦子精品免费 | 国产精品免费av | 午夜视频在线 | 美女扒开内裤让男人桶 | 成 人 黄 色 大片 | 黄色综合网站 | 日本黄色网战 | 久久精品人人做人人 | 99热这里有精品 | 欧美zzzz | 精品免费国产一区二区三区四区介绍 | 久章操 | 久久在线观看 | 精品天堂 | 片一级片在线观看 | 成人在线视频网 | 日韩欧美中 | 精品国产一区二区三区久久久蜜臀 | 日本中文字幕视频 | 亚洲综合精品一区 | 免费国产一级特黄久久 | 久草福利站 | 国产偷久久一级精品60部 | 国产精品久久久久久久免费大片 | 欧美一区二区三区四区视频 | 亚洲视频区|